Close Menu

Personalis NeXT Dx Test

Personalis has launchedthe NeXT Dx Test, a next-generation sequencing panel designed to help oncologists identify potential therapies and clinical trial options for cancer patients. The assay analyzes approximately 20,000 genes in both the tumor exome and transcriptome, and includes advanced analytics to provide a diagnostic report on genetic alterations in medically important cancer genes, as well as emerging immunotherapy-related biomarkers such as microsatellite instability status and tumor mutational burden.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.